RYZ401 for advanced neuroendocrine tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a neuroendocrine tumor (NET) that is grade 1, 2, or 3 and has spread or cannot be removed with surgery.
- Your tumor must show somatostatin receptors (SSTR) on a PET scan.
- You have not had treatment with Lu-177 or any other targeted radiation therapy before.
- You have not had a solid organ or bone marrow transplant, and you do not have liver cirrhosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Hear when a new GEP-NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.